title: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.
abstract: OBJECTIVE
  The phosphoprotein p53 is involved in transcriptional regulation and is detected in hematologic malignancies. In vitro incubation of acute myelogenous leukemia with OL(1)p53, a 20-mer phosphorothioate oligonucleotide complementary to p53 mRNA, results in leukemic cell death. A phase I dose-escalating trial was conducted to determine the toxicity of OL(1)p53 following systemic administration to patients with hematologic malignancies.
  
  
  METHODS
  Sixteen patients with either refractory acute myelogenous leukemia (n = 6) or advanced myelodysplastic syndrome (n = 10) participated in the trial. Patients were given OL(1)p53 at doses of 0.05 to 0.25 mg/kg/h for 10 days by continuous intravenous infusion.
  
  
  RESULTS
  No specific toxicity was directly related to the administration of OL(1)p53. One patient developed transient nonoliguric renal failure. One patient died of anthracycline-induced cardiac failure. Approximately 36% of the administered dose of OL(1)p53 was recovered intact in the urine. Plasma concentrations and area under the plasma concentration curves were linearly correlated with dose. Leukemic cell growth in vitro was inhibited as compared with pretreatment samples. There were no clinical complete responses.
  
  
  CONCLUSIONS
  A phosphorothioate oligonucleotide, OL(1)p53, can be administered systemically without complications. This type of modified oligonucleotide can be administered without complete degradation, as it was recovered from the urine intact. This oligonucleotide may be useful in combination with currently available chemotherapy agents for the treatment of malignancies.
authors.affiliation: University of Nebraska Medical Center, Omaha, NE, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop
authors.forename: P L
authors.initials: PL
authors.lastname: Iversen
authors.forename: E
authors.initials: E
authors.lastname: Bayever
authors.forename: J G
authors.initials: JG
authors.lastname: Sharp
authors.forename: T C
authors.initials: TC
authors.lastname: Greiner
authors.forename: B L
authors.initials: BL
authors.lastname: Copple
authors.forename: R
authors.initials: R
authors.lastname: Ruddon
authors.forename: G
authors.initials: G
authors.lastname: Zon
authors.forename: J
authors.initials: J
authors.lastname: Spinolo
authors.forename: M
authors.initials: M
authors.lastname: Arneson
authors.forename: J O
authors.initials: JO
authors.lastname: Armitage
authors.forename: A
authors.initials: A
authors.lastname: Kessinger
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D013873:Thionucleotides / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D016896:Treatment Outcome
chemical_list: D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides; C086760:OL(1)p53